KALV earnings analysis
What we found in KALV's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
KalVista Pharmaceuticals, Inc. reported a substantial increase in revenue to $40.9 million in Q1 2026, a dramatic contrast to zero revenue in the prior year due to the successful launch of EKTERLY, their first oral therapy for hereditary angioedema. Despite this revenue growth, the company still posted a significant operating loss and EPS of -0.53, reflecting ongoing high expenditures, particularly in administrative costs related to commercialization.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Surge
- Total revenue increased to $40.9 million in Q1 2026, up from $0 million in Q1 2025.
- Product Launch Success
- Product revenue from EKTERLY contributed $39.2 million, marking a successful U.S. and German market entry.
- Reduced Operating Loss
- Operating loss decreased to $23.4 million from $49.7 million year-over-year, an improvement of 53%.
- Decreased R&D Expenses
- R&D expenses fell by 12% to $12.4 million, down from $14.2 million in Q1 2025.
- Increased Stable Cash Reserves
- As of March 31, 2026, cash reserves stood at $285 million, providing sufficient liquidity for upcoming operations.
- Partnership Revenue Growth
- Partnership and other revenue reached $1.7 million, up from $0 million in the same quarter last year.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Cash Burn Rate
- KalVista reported cash used in operating activities of $14.5 million, although it improved from $47.6 million year-over-year.
- Pending Merger Uncertainty
- The merger with Chiesi, valued at roughly $1.9 billion, could face regulatory challenges or delay completion, potentially impacting stock value.
- Increased SG&A Costs
- Selling, general, and administrative expenses rose by 37% to $48.8 million, raising concerns about long-term profitability.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.53
- Segment
- Product revenue: $39.2 million
- Segment
- Partnership revenue: $1.7 million
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads better than the one before it.
What came before.
- 10-K · April 30, 2026
- KalVista Pharmaceuticals, Inc. reported strong revenue growth in its Q2 2026 results, achieving $14 million in revenue, a significant increase from $1 million in the previous quarter. Despite ongoing financial losses…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing KALV makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever